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Abstract 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible loss of lung 
function that stem from two mechanisms, inflammation and senescence. Crosstalk between 
these two mechanisms accelerate the development of COPD, thus targeting these two 
pathways may offer benefits in the treatment of COPD. Growing amount of evidence have 
shown that mesenchymal stem cells as a promising candidate for the treatment of COPD.  
Over the years, many studies conducted to decipher the therapeutic effect of MSC in COPD 
and the mechanisms involve, in the hope of utilizing these cells as new therapeutic strategy 
for COPD. However, the cell-based therapy by using the MSC presented with many 
obstacles including low engraftment at the site of injury, the risk of microvascular occlusion, 
unwanted differentiation, and also the risk of malignant transformation. Recently, recently 
researchers begin to look at the possibility of using MSC derived extracellular vesicles as an 
alternative to MSC. Here we review the effect of MSC and MSC derived EV in modulating 
inflammation, and senescence in COPD. We also review current treatment and the side 







Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) has a tremendous economic impact on 
healthcare and is associated with high morbidity, and high mortality rate. Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) in 2017 reported that more than 3 million people 
died in 2012 accounting for 6% of total death globally. It is estimated that the prevalence and 
the burden of COPD to increase in the coming decade and by 2020, COPD will become the 
third leading cause of death worldwide. Symptoms of COPD include chronic cough, dyspnea 
and excessive production of sputum, while anorexia, fatigue and weight loss may present in 
patient with severe COPD. The diagnosis of post-bronchodilator forced expiratory volume in 
one second (FEV1)/ forced vital capacity (FVC) ≤0.7 confirms the presence of airflow 
limitation. The body mass index (BMI) are also useful in predicting outcomes such as 
survival with the values <21 kg.m-2 are associated with increased mortality (Celli et al., 2004). 
Cigarette smoke is the main risk factor of COPD which accounts for 80-90% of all cases. 
However, environmental pollution, noxious gases, genetic predisposition, pulmonary 
infections, and aging can also increase the risk of COPD (Churg et el.,2008).  
The hallmark of COPD is chronic inflammation in the lung that leads to chronic bronchitis and 
emphysema. Chronic bronchitis is linked to the chronic inflammatory cells infiltration in small 
bronchi, leading to abnormal remodelling and mucus overproduction. Meanwhile 
emphysema is associated with irreversible alveolar structures that contributes to airspace 
enlargement without significant pulmonary fibrosis. These pathological changes lead to 
progressive airflow limitation however, the severity varies between patients (Grove et al., 
2009). Apart from inflammation, senescence also plays an important role in the pathogenesis 
of COPD. Aging individuals are shown to be at higher risk of developing COPD as 
demonstrated by Hardie et al., (2002) in the study with 35% of healthy, never smoker, 
asymptomatic aged 70 years and older suffer with at least stage 1 COPD. Increase burden 
of COPD in elderly might be attributed to 1) Age-related changes in lung structure and 
function may increase the pathogenetic susceptibility to COPD and 2) Exposure to external 
insults render the elderly population to become vulnerable to lung injury (Fukuchi et al., 
2009). Furthermore, cigarette smoke also contributed to premature lung aging by increasing 
the oxidative stress and DNA damage thereby inducing senescence (Hara et al., 2013). 
Senescence cells produced various pro inflammatory cytokines that accelerate inflammation 
and thus contribute to the chronic condition of COPD (Tsuji et al., 2010). 
 
 
Inflammation in COPD 
Inhalation of cigarette smoke or noxious gases incite the innate and adaptive immune 
system which in long term will cause destruction to the respiratory system. Cigarette smoke 
accelerates the production of reactive oxygen species (ROS) and increased the oxidative 
stress. This will induce cellular dysfunction or cell death and disrupts the proteinase-
antiproteinase imbalance by activating proteases and inactivating antiproteinases 
(D’Agostino et al., 2010). Neutrophils, macrophages, and CD8+ T cells are prominent player 
in COPD exacerbation, however, CD4+ T cells, regulatory T (Treg) cells, and dendritic cells 
(DC) may also contribute to the COPD pathogenesis. Acute inflammation takes place at the 
initial smoke exposure and peaked at the end of first week and chronic inflammation begin 
after 2 weeks of exposure. Neutrophils influx, thickening of epithelial wall and goblet 
hyperplasia were also observed during acute inflammation (Stevenson et al. 2007). 
Exposure to cigarette smoke induced epithelial cells to produce inflammatory mediators 
including interleukin (IL)-8, GM-CSF, IL-6, IL-1β (Mortaz et al., 2011). Interleukin 8 is a 
potent chemoattractant to neutrophils which can induce secretion of myeloperoxidase by 
neutrophils that can attract more inflammatory cells to sustain the inflammation (Quint et al., 
2007). Subsequently, tissue macrophages begin to increase, triggering chronic inflammation. 
Collagen deposition, lymphocytes infiltration and macrophage aggregation were reported to 
be elevated (Stevenson et al. 2007). Macrophages release IL-8, IL-6, TNF-α, monocyte 
chemotactic peptide-1 (MCP-1), matrix metalloprotease (MMP)-9, MMP-12, and ROS that 
leads to the destruction of lung parenchyma (Angelis et al., 2014). Meanwhile, type 1 
cytotoxic T (Tc1) cells that predominate lung parenchyma, release granzyme B and perforins 
that may induce apoptosis to alveolar epithelial cells and thus contribute to emphysema 
(Majo et al., 2001). In addition, cigarette smoke exposure increased the accumulation, 
activation and maturation of DC in lung and in turn, DC communicate with T helper (Th) 1 
cells, Th2 cells, and Treg cells to release numerous cytokines including IL-4, TNF-α, IFN-γ, 
increase mucus secretion, and development of tolerance to infection (Tsoumakidou et al., 
2008). 
There is evidence of persistent inflammation after smoking cessation, although the 
mechanism has not yet been established (Lapperre et al., 2006). The number of plasma 
cells, and CD3+ and CD4+ lymphocytes are higher in the ex-smokers with COPD as 
compared to current smokers with COPD. Additionally, the number of macrophages, 
neutrophils, mast cells, eosinophils and CD8+ lymphocytes are also similar to the current 
smokers. Furthermore, elevation of GM-CSF, CSF-1, IL-17A, serum amyloid A after smoking 
cessation, have been implicated in sustained macrophages proliferation and neutrophil 
recruitment (Hansen et al., 2014). Persistent apoptosis in airway epithelial cells and T cells 
were also seen in smoking cessation group as compare to control group. Apoptosis of T cells 
may result in reduced immune response to external insults leading to increased risk of 
infection in COPD (Zuo et al., 2014). Evidence have shown that, reduced number of Treg cells 
has been implicated in autoimmunity. Regulatory T cells is the key player in regulation of 
inflammation in autoimmune disorders. Suppression of immune function occur via 
modulation of maturation and function of antigen presenting cells (APC), metabolic pathway 
disruption, killing of target cells, and anti-inflammatory cytokine secretion (Grant et al., 2015).  
In emphysematous lung of COPD patients, reduced level of FOXP3 mRNA, a transcription 
factor for Treg cells development, reduced number of Treg cells, as well as reduced IL-10 were 
observed, indicating autoimmune reaction in lung (Lee et al., 2007).  
 
Senescence in COPD 
The concept of cellular senescence arose from the research by Leonard Hayflick and Paul 
Moorhead that demonstrated normal human fibroblast cells in in vitro culture have a limited 
lifespan (Hayflick, 1965).  When cells ceased to proliferate, it enters the state of irreversible 
growth arrest. Morphologically, senescent cells size is bigger than normal cells and adherent 
cells often exhibit a flattened shape. Senescence cells resist apoptosis and remain 
metabolically active, as well as excreting senescence associated secretory phenotype 
(SASP) (Kirkland et al., 2017). Growth arrest of senescent cells happen at G0/G1 phase of 
cell cycle. Senescence cells can be identified by a histochemical staining; Senescence-
associated β-galactosidase (SA-βgal). Mammalian cells regardless age express lysosomal 
β-galactosidase when stained with 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal) 
at pH 4. However senescence cells stained positive by X-gal at pH 6 caused by an increased 
lysosomal β-gal activity but is not demonstrated in actively proliferating cells and quiescent 
cells (Lee et al., 2006). 
 
The number of senescent cells increase with age, however, senescence can also be induced 
in vivo and in vitro by using numerous stimulants including beryllium, bromodeoxyuridine, 
hydrogen peroxide, and cigarette smoke (Ross et el., 2008, Sun et al., 2015, Coates et al., 
2007, Ahmad et al., 2015). These stimulants may induce reactive oxygen species (ROS), 
telomere attrition, DNA damage response (DDR), oncogenic-induced senescence, CDKN2A 
derepression, and senescence-associated secretory phenotypes (SASP) which will trigger 
the activation of p53/p21, and p16INK4A/pRb signalling pathways that lead to senescence. 
Activation of these pathways inhibit the expression of cyclin-dependent kinases (CDKs) 
including CDK1, CDK2, CDK4, CDK6, Cyclin A, Cyclin E, and Cyclin D, which in turn 
suppress the phosphorylation and preventing the activation of retinoblastoma protein (Figure 
1) (Campisi et al., 2007, Lujambio et al., 2016).  
 
 
Figure 1: p53/p21 and p16/pRb signalling pathways. Multiple stress signal can trigger the 
activation of p53 and p16, in which both pathway may act downstream to inhibit CDKs and 
retinoblastoma protein (Lujambio et al., 2016). 
 
This sophisticated mechanism is natural cell response to damaging stimuli that may cause 
mutation resulting in tumour formation. Senescence plays a role in tumour suppression in the 
early stage of tumour formation by preventing the proliferation of damaged cells. Activation of 
p53/p21 through DDR, arrests the human colon adenocarcinoma cells at G1 phase of cell 
cycle (Waldman et al., 1995). Meanwhile, the induction of oncogenic H-Ras (V12) in primary 
human and rodent cells leads to G1 cell cycle arrest, increased expression of p53 and p16 
which result in premature senescence (Serrano et al., 1997). Inactivation of p53 however, 
bypasses the onset of cellular senescence and leads to oncogenic transformation and 
restoring p53 function regress the tumour without affecting normal tissues (Ventura et al., 
2007).  Conversely, the failure of eliminating senescent cells can be damaging. The 
accumulation of senescent cells over time will cause damage to the tissue and result in age-
related diseases and tumour formation. Senescent fibroblasts have been shown to stimulate 
the proliferation and progression of preneoplastic and neoplastic cells (Krtolica et al., 2001). 
This in part appear to be mediated by SASP released by senescence cells which contains 
numerous soluble factors including proinflammatory cytokines, chemokines, growth factors 
and matrix degrading proteins (Coppe et al., 2008). SASP has been shown promotes 
epithelial-mesenchymal transition (EMT) and stimulate the invasion of tumour cells by the 
action of two secreted cytokine; interleukin (IL) -6 and IL-8 (Coppe et al., 2008). 
Senescence play a significant role in the pathogenesis of COPD by altering the cellular 
functions and contribute to the chronic inflammation. In aging lung, alveolar structures are 
altered, reduced respiratory muscle strength, modification of extracellular matrix composition, 
vascular remodelling, reduced lung function, and impaired capacity of gas exchange. This in 
part, might explain why aging population has higher risk in developing COPD (Karrasch et 
al., 2008). In addition, long term exposure to cigarette smoke will accelerate telomere 
shortening in type II alveolar epithelial cells (AEC type II) that will cause senescence in type 
II alveolar epithelial cells. As a result, senescence AEC type II may contribute to insufficient 
regeneration of alveolar cells which in turn leads to emphysema (Tsuji et al., 2006). Cigarette 
smoke disrupt many proteins and enzymes level which may accelerate cellular senescence 
in lung. Brain type-creatine kinase (CKB) that is involve in energy homeostasis of cells, has 
been shown to be associated with acceleration of bronchial epithelial cells senescence. 
Depletion of CKB induced p21 expression, G2/M cell cycle arrest, accumulation of protein 
involves in mitosis, Cyclin B1, that cause cells to become senescent as well as increased 
level of IL-8 (Hara et al., 2012). In addition, exposure of lung fibroblast and small airway 
epithelial cells (SAEC) to cigarette smoke extract also lead to interaction of p53 and E3 
ubiquitin ligase (Parkin). This interaction will reduce Parkin translocation to damaged 
mitochondria, hence impairing damaged mitochondria clearance, thus accumulation of 
senescent cells (Ahmad et al., 2015). In mice model exposed to cigarette smoke for 6 
months, significant decreased of sirtuin 1 (SIRT1) was observed. Sirtuin 1 is NAD+-
dependent protein/histone deacetylase that involves in wide range of processes including 
aging and inflammation (Rajendrasozhan et al., 2008). Sirtuin 1 has been shown to interact 
with FOXO3 and p21 in mitigating senescence in emphysematous lung. However, the 
absence of FOXO3 and p21 deficiency, SIRT1 failed to exert its effect, thus accelerating 




Interaction between inflammation and senescence 
Chronic inflammation has been implicated in senescence and accelerate ageing. Many age-
related diseases such as Alzheimer’s disease, diabetes type-2, atherosclerosis, and 
Parkinson’s disease presented with chronic, low-grade inflammation as an important 
mechanism responsible for the disease progression (Ikeno et al., 2011). Various pro-
inflammatory mediators such as IL-6, TNF-α, CXCR-2, IFN-γ, and TGF-β collectively 
aggravate the inflammation and senescence. NF-κβ as the master regulator of many gene, 
cytokines, adhesion molecules, enzymes, many of which related to inflammation as well as 
apoptosis (Serasanambati et al., 2016), may also play a role in inducing senescence. In 
addition, chronic inflammation also exhibited increased expression of p21 and p16, and 
downregulation of anti-inflammatory cytokines, IL-4 and IL-10 (Jurk et al., 2014). Prolonged 
treatment of IFN-γ in HUVEC enhanced oxidative stress, and arrested cells in G0/G1 phase 
of cell cycle thus inducing cellular senescence through p53/p21 pathway, and not p16 (Kim 
et al., 2009).  Meanwhile, tumor necrosis factor-α also increase number of senescent 
endothelial cells, induced p21 expression, and endothelial dysfunction (Yamagata et 
al.,2016). However, TNF and IFN-γ alone unable to induced senescence in murine breast 
cancer. Combination of TNF and IFN-γ are needed in order to successfully halt the cancer 
progression by arresting cell cycle at G0/G1 phase, activating p16INK4a/Rb pathway, thus 
inducing senescence (Braumuller et a.,2013). 
Senescence has also been shown to contribute in inflammation through the production of 
SASP. mRNA level of SASP components such as IL-6, IL-8, MCP-1, IL-1β, MMP-3, MMP-
12, and TNF-α increased significantly in senescent cells (Xu et al., 2015). In the lung of 
aging mice, cDNA array analysis demonstrated that 8 genes including CD20, CXCR-3, 
CD72, IL-8RB, and C-Fgr that are related to inflammation were upregulated. Increased 
number of CD8 cells, CD4 cells, macrophages, and B cells were also been observed 
(Aoshiba et al., 2007). Cigarette smoke induced cellular senescence in type II alveolar 
epithelial cells by increasing the expression of P16INK4a and phosphorylated NF-κB, along 
with pro-inflammatory cytokines IL-6, IL-8, and TNF-α (Tsuji et al., 2010). Senescence 
pulmonary vascular endothelial cells exhibited increase p16 and p21 mRNA expression, 
shorter telomeres, reduced telomerase activity, and also excreted increase level of IL-6, IL-8, 
MCP-1, Hu-GRO, and soluble ICAM-1. Enhanced secretion of soluble ICAM-1 and MCP-1 
led to increase monocyte adherence and migration which in turn will aggravate inflammation 
(Amsellem et al., 2011). 
 
 
Current treatment for COPD 
The main objectives of COPD management are focusing on reducing symptoms and 
exacerbation, preserving lung function decline, reducing mortality while increasing exercise 
capacity and improving health status. Smoking cessation remains to be an effective 
intervention for COPD as it results in improved FEV1, reduction in hospital admission, lower 
prevalence of cough, sputum production, wheezing and shortness of breath (Gotfredsen et 
al., 2002, Kanner et al., 1999). A wide range of pharmacotherapeutic drugs are also 
available for the treatment of COPD, such as bronchodilators, muscarinic antagonist, and 
corticosteroids, however, the administration of these drugs is often associated with adverse 
effect.  
Bronchodilators is a type of drugs that promotes airway smooth muscle relaxation and 
improved lung emptying during tidal breathing. Common bronchodilators include 
anticholinergic drugs, beta2 agonists and methylxanthine which can be administered orally, 
inhalation or by injection. Short-acting beta2 agonists such as salbutamol and fenoterol 
provides a quick relief from symptoms. On the other hand, long-acting beta2 agonists such 
as salmeterol and formoterol help to control persistent symptoms but do not provide quick 
relief (Ejiofor et al., 2013). Theophylline, a type of methylxanthine is a long-acting 
bronchodilator used to treat airway disease. However, to achieve significant 
bronchodilatation as beta2 agonist, relatively high plasma concentrations are needed (10–20 
mg/l) (Barnes, 2006).  
Muscarinic antagonist exerts its action by blocking the bronchoconstrictor effects of 
acetylcholine on M3 muscarinic receptors. Ipratropium bromide, the most common short-
acting muscarinic agonist (SAMA) exerts its action within minutes and last for approximately 
4 hours. (Ejiofor et al., 2013). According to the Lung Health Study, regular ipratropium use 
has no effect on the rate of decline of lung function over time in mild to moderate COPD. 
Meanwhile, long-acting muscarinic antagonists like tiotropium and aclidinium bromide have a 
longer duration of action of over 24 hours due to prolong binding to the M3 muscarinic 
receptor and faster dissociation from M2 muscarinic receptor. On the other hand, inhaled 
corticosteroids (ICS) are prescribed in high doses for COPD, however beneficial effect in 
patient is controversial as it does not effective in slowing the reduction in lung function. 
Combination of ICS and beta2 agonist is effective in improving lung function and reducing 
exacerbation in patient with moderate to severe COPD as compared to single component 
(Nannini et al., 2007). In a double-blind cross over study, Culpitt and colleagues (1998) 
examined the effect of 500µg fluticasone propionate which given twice a day for 4 weeks. 
There are no changes in sputum supernatant elastase activity, anti-proteases secretory 
leukoprotease inhibitor (SLPI), matrix metalloproteinase (MMP)-1, MMP-9 and tissue 
inhibitor of metalloproteinase (TIMP)-1, suggesting that ICS has no benefit in reducing 
inflammation.   
 
Side effect of COPD drugs 
Generally, bronchodilators are well tolerated. However, several studies reported multiple 
adverse effect on patient prescribed with bronchodilators. Chest pain, headache, and 
syncope were experienced by patient prescribed with formoterol (Thomson et al., 1998) and 
cardiac rhythmic disturbance was reported in patient prescribed with terbutaline (Lipworth et 
al., 1990). Long acting beta2-agonist may cause higher heart rate, and supraventricular or 
ventricular premature in COPD patient with pre-existing arrhythmia and hypoxemia (Cazzola 
et al., 1998). Administration of theophylline is associated with headache, abdominal 
discomfort, nausea and vomiting, and restlessness, increased acid secretion, 
gastroesophageal reflux, and diuresis. Convulsions, cardiac arrhythmias, and death may 
occur at high concentration. These side effects are due to the increase of plasma 
concentration (Barnes, 2005). 
 
Dry mouth is the most common side effect of muscarinic agonist. A 4-year trial of tiotropium 
in COPD patient reported adverse effect including pneumonia, dyspnea as well as dry mouth 
and constipation (Tashkin et al., 2008). A randomized controlled trial on ipratropium and 
tiotropium suggested an increased risk of myocardial infarction, cardiovascular death, and 
stroke (Singh et al., 2008), while another study reported no significant effect of triotropium on 
cardiovascular mortality, myocardial infarction, and respiratory mortality, although dyspnea, 
dry mouth and upper respiratory tract infection were observed (Kesten et al., 2006). A 
comparison study between indacaterol and triotropium showed that both drugs produced 
similar side effects such as cough, nasopharyngitis, COPD exacerbation, headache, 
influenza, and bronchitis (Dunn et al., 2010). A 24-weeks, randomized, placebo-controlled 
study demonstrated that aclidinium bromide is associated with multiple adverse effect 
including cough, headache, nasopharyngitis, urinary tract infection, diarrhea, muscle spasm, 
dyspnea, and nausea (D D’urzo et al., 2014). Evidence suggested that there is increase of 
fractures in COPD patient when treated with ICS (Loke et al., 2011). The use of ICS is also 
associated with increased risk of pneumonia; however, the risk declines gradually after 
stopping the ICS use (Suissa et al., 2013). A study using fluticasone furoate depicted 
increase risk of pneumonia, fractures, and nasopharyngitis in fluticasone furoate only group, 
and fluticasone furoate/vilanterol group (Dransfield et al., 2013). Skin bruising, oropharyngeal 
candidiasis and throat irritation were also prominent in COPD patient prescribed with high 
dose of ICS (Pauwels et al., 1999). 
 
Senolytic drugs as a new therapy in eliminating senescent cells 
Recently, research begins to look at the possibility of developing new pharmacological 
strategies that are able to selectively eliminate senescent cells without harming healthy 
quiescent and proliferating cells. This strategy is thought to be beneficial as senescent cells 
have been implicated in the development of chronic diseases and tumour formation. Since 
senescent cells resist apoptosis, a study was conducted to analyse pro-survival markers in 
senescent cells including ephrin ligands (EFNB1 and EFNB3), PI3KCD, p21, Bcl-2, PAI-1, 
and PAI-2. Administration of drugs or silencing these markers, killed senescent cells without 
harming proliferating cells and quiescent cells (Zhu et al., 2015). Since then, more studies 
have been done to identify drugs that can potentially be used in killing senescent cells 
including dasatinib, quercetin, navitoclax, and 17-DMAG. 
Zhu and colleagues (2015) found out that dasatinib and quercetin were able to reduce 
senescent cells number. Dasatinib and quercetin were tested in experimental lung fibrosis 
model, in which combination of dasatinib and quercetin reduced senescent cells number, 
decreased level of p16, reduced expression of SASP components such as IL-6, MMP12, 
SPP1, serpine 1, collagen 1a1, collagen 5a3, fibronectin, increased level of caspase 3, and 
increased epithelial cell marker E-cadherin, AECII markers SFTPC and SFTPA (Lehmann et 
al., 2017). Fuhrmann-Stroissnigg and colleagues (2017) recently identified HSP90 inhibitor, 
17-DMAG as a potential new senolytic drug in which the treatment of senescent MEF with 
17-DMAG selectively induced apoptosis in these cells, as well as murine MSCs, IMR90, and 
human lung fibroblast cells (WI38). 17-DMAG also reduced the expression of p16INK4a, SASP 
component IL-6, DNA damage marker γH2AX, and reduced p-AKT level. Administration of 
17-DMAG in progeroid mouse model, decreased age-related symptoms including, tremor, 
ataxia, gait disorder, dystonia, and kyphosis (Fuhrmann-Stroissnigg et al., 2017). Navitoclax 
and TW-37, member of Bcl-2 family inhibitor have been tested in in vitro setting by using 
human umbilical vein epithelial cells (HUVEC), human lung fibroblast (IMR90), murine 
embryonic fibroblast (MEF) and preadipocytes. Navitoclax induced apoptosis in HUVEC, 
IMR90, MEF, but not preadipocytes. TW-37 however, has very little senolytic effect over 
these cells, which may be due to different in level of targets between navitoclax and TW-37 
(Zhu et al., 2016). In addition, dasatinib is more effective in eliminating senescent cells in 
preadipocyte and less effective in senescent HUVEC. Meanwhile quercetin kills senescent 
HUVEC but not effective against senescent preadipocyte (Zhu et al., 2015). A more recent 
study demonstrated that, BCL-XL inhibitors, A1331852 and A1155463 induced apoptosis in 
senescent HUVEC and IMR90, but not senescent preadipocyte (Zhu et al., 2017). In 
addition, another HSP90 inhibitor, ganetespib reduced the viability of senescent HUVEC, but 
not preadipocyte (Fuhrmann-Stroissnigg et al., 2017). This indicates that senolytic drugs is 
cell specific, targeting different proteins and pathways. However, many of these drugs have 
been used in treating other diseases such as leukemia, lung cancer, and ovarian cancer, 
which can cause side effects (Aguilera et al., 2009, Niu et al., 2009, Rudin et al., 2012). It is 
not clear however, if these drugs can be used in the treatment of COPD. 
 
Mesenchymal Stem Cells 
Mesenchymal stem cells are multipotent adult stem cells with fibroblast-like morphology that 
can be found mainly in the bone marrow. International Society of Cellular Therapy has 
proposed three minimal criteria to define mesenchymal stem cells (MSCs); I) MSC is plastic 
adherent under standard culture condition. II) MSC should expressed CD73, CD90 and 
CD29 and III) MSC are capable of differentiating into osteocytes, chondrocytes,   and   
adipocytes (Wuchter et al., 2013). Mesenchymal stem cells possess the ability to modulate 
innate and adaptive immune systems mediated by cell-to-cell contact and the secretion of 
paracrine factors. Interaction of MSC with immune cells produced myriad of effects such as 
enhanced differentiation of B lymphocytes into plasma cells, impaired function of dendritic 
cells, inhibition of T lymphocytes proliferation, as well as enhanced respiratory burst activity 
of macrophages (Vasandan et al., 2016, Bonnaure et al., 2016, Tabera et al., 2008, Jarvinen 
et al., 2008). In addition, MSC are also capable of homing to the site of injury, and the lack of 
Major Histocompatibility Complex class II (MHCII) expression and low expression of MHCI 
makes MSC hypoimmunogenic and thus escape immune recognition (Pittenger et al., 1999, 
Zhao et al., 2016). 
In the past decade, studies have been conducted in preclinical and clinical settings for the 
treatment of various disease including GVHD, diabetes, neurological disorders, heart 
diseases, cancers, and lung diseases. Whilst the results have been encouraging, there are 
still major challenges to overcome before stem cell-based therapy can be translated into 
clinical settings. One of the major concern of with cell-based therapy using MSC is the risk of 
malignant transformation. Prolonged culture of MSC have shown to spontaneously 
transformed itself in vitro and when transplanted in mice model, the cells formed 
fibrosarcoma with p53 mutation (Li et al., 2007). Another study has also reported unwanted 
differentiation in transplanted MSC in mice model of myocardial infarction which resulted in 
calcification and bone formation at the injury site (Breitbach et al., 2007). These unregulated 
growths are thought to occur due to genetic and epigenetic changes during handling and 
cultivation of stem cells (Mousavinejad et al., 2016). In addition, the engraftment of MSC in 
the injury area appeared to be low is insufficient to account for therapeutic response, 
suggesting paracrine-mediated mechanism of MSC (van Haaften et al., 2009). Furthermore, 
study demonstrated that administration of MSC resulted in immediate death of the animal 
due to pulmonary embolism associated with large size of MSC or cellular clumping (Antunes 
et al., 2014). 
 
Mesenchymal stem cells in the treatment of COPD 
Research on MSC as a new therapeutic regiment for COPD is currently focusing more on 
ameliorating the inflammation. The effect of MSC in mitigating the inflammation have been 
extensively studied in preclinical settings and tested in clinical trial all over the world. 
Attenuation of inflammation and increase secretion of cytokines involve in tissue repair by 
MSC significantly improved lung function, and stimulate the lung tissue regeneration (Liu et 
al., 2016). Besides ameliorating inflammation, MSC have a remarkable regenerative 
capability to differentiate into functional type II alveolar epithelial cells with the ability to 
express surfactant-related genes and proteins (Cerrada et al., 2014). Destruction of alveolar 
wall in elastase induce emphysema leads to reduction in pressure of arterial oxygen (PaO2) 
and alveolar-arterial oxygen gradient (A-aDO2) which will impair the pulmonary function. 
Regeneration of alveolar wall by MSC restore the pulmonary function by increase PaO2 and 
A-aDO2 level, and decrease the mean linear intercept (Furuya et al., 2012). 
Although MSC have shown a tremendous benefit in preclinical studies, a recent phase II, 
randomized, double-blind, placebo-controlled study was conducted on 62 moderate-to-
severe COPD patients receiving intravenous allogeneic MSC appeared to be safe with no 
significant adverse effect, and no increase in exacerbation. However, there is no significant 
difference in pulmonary function test and quality of life, although there is decreased in 
circulating C-reactive protein which indicate there is anti-inflammatory effect of MSC on 
systemic inflammation (Weiss et al.,2013). However, a more recent phase I study to evaluate 
the safety of MSC administration after lung volume reduction surgery for severe emphysema 
demonstrated an increased in FEV1 after 12 months follow up, and a 3-fold increase of 
CD31 in alveolar septa which indicates responsiveness of microvascular endothelial cells to 
MSC treatment (Stolk et al., 2016).  
Although MSC are capable of attenuating the inflammation in COPD, it is unknown whether 
MSC can regulate the senescence in COPD. Recently, an in vitro study was conducted to 
determine the effect of MSC in hypoxia/reoxygenation-induced premature senescence in 
cardiomyocyte. Co-culture of MSC have been shown to reduce the number of senescent 
cardiomyocytes and decreased expression of p53 and p21. However, MSC do not have any 
effect of p16, suggesting that MSC exert its effect via p53/p21Cip1/Waf1 pathway but not 
p16INK4a/Rb pathway (Cai et al., 2012). This encouraging evidence led to in vivo study by the 
same group using natural aging rat model. Four months old and 20 months old Sprague 
Dawley (SD) rat was used as young and natural aging model respectively. Consistent with 
previous result, transplantation of MSC inhibit oxidative stress, as well as reduced the 
expression of senescence markers p53 and p21, but not p16. Mesenchymal stem cells also 
significantly decreased senescent cells number and normalized endogenous anti-oxidant 
activity. Attenuation of senescence effect on aging heart improved cardiac function, cardiac 
hypertrophy and fibrosis as evident in MSCs treated group (Zhang et al., 2015). In addition, 
another study has been conducted in premature aging model of Bmi-1 deficiency. 
Mesenchymal stem cells transplantation in Bmi-1 deficiency mice, inhibits apoptosis while 
migrating into multiple organs, proliferate, and differentiate into various cells, thus promoting 
growth and delay senescence. Mesenchymal stem cells also downregulate senescence 
markers p16, p19, and p27 expression as well as Wnt16, prolonged the survival rate, 
increased body weight, increased proliferation of thymocyte and renal cells, ameliorate 
skeletal growth and development retardation, improved dysmaturity of T lymphocytes, 
decreased intracellular ROS level and hydrogen peroxide level, and increased level of anti-
oxidant, superoxide dismutase and catalase (Xie et al., 2015).  
 
Therapeutic application of mesenchymal stem cells derived extracellular vesicles in 
lung diseases 
Due to the limitation faced in cell-based therapy, much focus has been diverted into the 
possibility of using extracellular vesicles (EV) released by MSC as a potential new 
therapeutic regiment for various diseases. Extracellular vesicles are small membrane 
vesicles released by various types of cells and also can be found in body fluids such as milk, 
saliva, urine, amniotic fluid and cerebral spinal fluid that is important for cell-to-cell 
communication. The size of EV range from 40-1000nm and can be sedimented by 
centrifugation at 100,000 g. The most prominent extracellular vesicles are exosome and 
microvesicles that contain various types of proteins, lipids, messenger ribonucleic acid 
(mRNA) and micro RNA (miRNA). These EV participate in many physiological and 
pathological processes including inflammation, cancer progression, immune responses, and 
angiogenesis (Ludwig et. al., 2011, Yu et. al., 2014). Extracellular vesicles are naturally 
stable due to its lipid membrane similar to the cells itself can easily be taken up by the cells. 
MSC derived EV also possess no risk of pulmonary embolism due to its small size, and do 
not contain nuclei, therefore, EV do not replicate, thus avoiding the risk of forming teratoma 
and unwanted differentiation as compared to MSC (Chen et al., 2011).  
To date, there is no report on the effect of MSC derived EV on inflammation and senescence 
in COPD, however, understanding how MSC derived EV exerts its function in other diseases 
may give an insight on the mechanism involved. Administration of MSC derived EV inhibited 
the vascular remodelling and hypoxic pulmonary hypertension model through the inhibition of 
transcription factor STAT-3, reduction of pro-inflammatory mediators MCP-1, IL-6, FIZZ-
1/HIMF, inhibition of pulmonary artery smooth muscle cells, and suppression of miR-17 (Lee 
et al., 2012). In influenza-induced lung injury, MSC derived EV inhibited the influenza 
replication in lung epithelial cells, reduced the level of TNF-α, CXCL-10, and increased the 
level of pro inflammatory cytokine IL-10, as well as inhibited the apoptosis of lung epithelial 
cells (Khatri et al., 2018). Similar findings demonstrated the ability of MSC derived EV to 
ameliorate pulmonary oedema and lung protein permeability in acute lung injury through 
reduction of total white blood cells count, neutrophils, and MIP-2, as well as increasing the 
IL-10. This therapeutic effect by MSC derived EV is thought to occur due to the transfer of 
EV’s content into the cells. MSC derived EV contain mRNA for keratinocyte growth factor 
(KGF) that involve in alveolar fluid clearance and blocking the KGF mRNA expression 
abrogated the effect of MSC derived EV. In addition, MSC derived EV are also able to 
provide therapeutic effect, and home to the site of injury following intravenous injection 
similar to MSC. (Zhu et al., 2014). Notably, MSC derived EV have been reported to induce 
lung adenocarcinoma cells growth by transferring miRNA-410 to the cells, resulted in 
increased proliferation rate, and lower apoptosis rate of the cells (Dong et al., 2018). 
However, conflicting result was reported in which MSC are inhibiting the lung tumour 
formation induced by chemical carcinogen (Liu et al., 2017). This contradicting effect in part 
may be due to the different source of MSC and different cargo content of EV. Del Fattore and 
colleagues (2015) demonstrated that bone marrow and umbilical cord MSC derived EV 
reduced the proliferation and increase apoptosis rate of glioblastoma cells, while adipose 
tissue MSC derived EV does not produce any effect, suggesting the role of tissue origin of 
MSC in mediating MSC derived EV effect (Del Fattore et al., 2015). In addition, a study 
conducted by Tofino-Vian et al., in 2017 to study the effect of MSC derived EV on 
osteoarthritic osteoblast induced by IL-1β showing a promising result in which MSC derived 
EV are shown to reduced the SA-β galactosidase activity and the accumulation of γH2AX 
foci, as well as downregulated the mitochondrial membrane changes and oxidative stress. 
 
Conclusion 
Considering the limitations of MSC, MSC derived EV could be a new therapeutic tool for the 
treatment of COPD. Although MSC derived EV have shown a tremendous effect in 
attenuating the inflammation and senescence in other model diseases, the effect of MSC 
derived EV on senescence in COPD is currently unknown. Thus, it is important to 
understand how MSC derived EV may exert its effect on inflammation and senescence in 
COPD. Long-term study should also be conducted to determine the safety and side effect 
that may occur with the administration of MSC derived EV. More studies should be done to 
standardize the culture condition of MSC, and methods of isolation of MSC derived EV as to 
maximize production of EV while maintaining normal phenotype. Optimal dosage, route of 
administration, and biodistribution of MSC derived EV should also be addressed before it can 
be translated into clinical settings. 
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